Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In-Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Balance at beginning at Dec. 31, 2020	$ 258,712	$ 4	$ 468,238	$ (3)	$ (209,527)
Balance at beginning (in shares) at Dec. 31, 2020		34,741,649
Exercise of stock options	750		750
Exercise of stock options (in shares)		140,128
Vesting of restricted stock	21		21
Issuance of common stock pursuant to ESPP purchases	373		373
Issuance of common stock pursuant to ESPP purchases (in shares)		18,950
Stock-based compensation expense	10,054		10,054
Net unrealized gain (loss) on short-term marketable securities	(24)			(24)
Net loss	(100,777)				(100,777)
Balance at ending at Dec. 31, 2021	169,109	$ 4	479,436	(27)	(310,304)
Balance at ending (in shares) at Dec. 31, 2021		34,900,727
Exercise of stock options	$ 5,238		5,238
Exercise of stock options (in shares)	559,145	559,145
Issuance of common stock pursuant to ESPP purchases	$ 280		280
Issuance of common stock pursuant to ESPP purchases (in shares)		33,928
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs	24,647		24,647
Issuance of common stock pursuant to equity investment by Pfizer, net of issuance costs (in shares)		2,525,252
Vested warrants issued pursuant to loan agreement	227		227
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees (shares)		8,846,154
Issuance of common stock upon closing of follow-on public offering, net of issuance costs and underwriting fees	215,787	$ 1	215,786
Stock-based compensation expense	23,243		23,243
Net unrealized gain (loss) on short-term marketable securities	64			64
Net loss	(112,033)				(112,033)
Balance at ending at Dec. 31, 2022	$ 326,562	$ 5	$ 748,857	$ 37	$ (422,337)
Balance at ending (in shares) at Dec. 31, 2022		46,865,206